

The health benefits of vitamin D greatly outweigh the health risks

William B. Grant, Ph.D.,¹ Cedric F. Garland, Dr. P.H., F.A.C.E.²

¹ Sunlight, Nutrition, and Health Research Center (SUNARC)

²Department of Family and Preventive Medicine 0631C, University of California San Diego, La Jolla, CA

In his recent essay, Trevor G. Marshall explores how vitamin D supplementation may be contributing to the current epidemics of obesity and chronic disease^[1]. Unfortunately, he has overlooked many important papers that disagree with his hypothesis. This letter points out some of the omissions.

The health benefits of vitamin D3 have been reviewed recently^[2]. The benefits for bone health have been known for nearly a century. Benefits for cancer, infectious diseases, autoimmune diseases, and metabolic diseases have been identified in the past three decades.

Starting in the 1980s, largely observational evidence mounted that solar ultraviolet-B (UVB) irradiance and vitamin D reduce the risk of many types of cancer^[3]. Based on observational studies, it is estimated that 1500 and 3600 International Units (IU) of vitamin D3 are required daily for a 50% reduction in risk of colorectal and breast cancer, respectively^[4]. A recent randomized, double-blind, placebo-controlled clinical trial that studied post-menopausal women in Nebraska found a 77% reduction in all-cancer incidence between the ends of the first and fourth years^[5], adding strong support to the observational studies.

Vitamin D enhances innate immunity through induction of human cathelicidin, LL-37^[1]. LL-37 helps control both bacterial and viral infections. A recent post-hoc analysis of vitamin D3 supplementation for post-menopausal women living in New York State found substantial benefits in reducing the common cold and influenza for 800 IU/day, and very strong benefits for 2000 IU/day^[6]. Benefits also appear to be strong for septicemia [Grant, submitted] and enteric viral infections such as norovirus [Grant, submitted], both of which are more frequent in winter than in summer.

Many autoimmune diseases appear to arise from an improper immune response to viral infections. Since LL-37 reduces the risk of viral infections, it may also influence the risk of autoimmune diseases such as multiple sclerosis. The well-known increase in prevalence of multiple sclerosis with increasing latitude is consistent with this hypothesis.

There is also a growing body of literature that low vitamin D status is a risk factor for many metabolic diseases, including hypertension, type 2 diabetes, and cardiovascular disease^[2]. A recent observational study found that vitamin D deficiency is associated with incident cardiovascular disease^[7].

There are some diseases where vitamin D supplementation may be contraindicated. These include granulomatous diseases such as sarcoidosis where local production of 1,25-dihydroxyvitamin D (calcitriol) in response to the disease can leak into the serum and dysregulate calcium metabolism^[8].

The current vitamin D3 fortification of food in the United States contributes an average of 250-300 IU/day to the American diet. This amount is too low to have a substantial beneficial effect on risk of cancer. Intake or production of vitamin D3 of 1000-2000 IU/day seems now appears to be required for optimal health, and typically will raise serum 25-hydroxyvitamin D (calcidiol) levels to 40-60 ng/mL^[4,6,9].

It is possible that there have not been more clinical trials of vitamin D supplementation clinical trials since there is little income in selling vitamin D3 (a year's supply of 1500 IU/day costs less than \$20 U.S.), and such trials are expensive.

The rising prevalence of obesity in the United States can be traced to two primary factors: replacing fat with simple carbohydrates in processed food and subsidy programs, in particular for growing corn and soybeans, that encourages overproduction of energy-dense foods and their sale at low cost^[10]. While these issues are addressed, increased vitamin D3 supplementation and fortification of foods will provide substantial health benefits, including reduced incidence of many serious diseases.

Disclosure

WBG receives funding from the UV Foundation (McLean, VA), the Vitamin D Society (Canada), and the European Sunlight Association.

References

1. Marshall TG. 2008. Vitamin D discovery outpaces FDA decision making. *Bioessays*. 30(2):173-82.
2. Holick MF. 2007. Vitamin D deficiency. *N Engl J Med*. 357(3):266-81.
3. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. 2006. The role of vitamin D in cancer prevention. *Am J Public Health*. 96(2):252-61.
4. Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC. 2007. What is the dose-response relationship between vitamin D and cancer risk? *Nutr Rev*. 65(8 Pt 2):S91-5.
5. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. 2007. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 85(6):1586-91.
6. Aloia JF, Li-Ng M. 2007. Re: epidemic influenza and vitamin D. *Epidemiol Infect*. 135(7):1095-6; author reply 1097-8.

7. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. 2008. Vitamin D Deficiency and Risk of Cardiovascular Disease. *Circulation*. [Epub ahead of print]
8. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS. 2007. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. *J Steroid Biochem Mol Biol*. 103(3-5):316-21.
9. Cannell J, Hollis B, Zasloff M, Heaney R. 2008. Diagnosis and treatment of vitamin D deficiency. *Expert Opin Pharmacother*. 9(1):107-18.
10. Pollan M. 2006. *The Omnivore's Dilemma; Natural History of Four Meals*. Penguin Press, New York. 430 pp.

Additional references in support of this letter:

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr*. 2006 Jul;84(1):18-28.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*. 2005 May 11;293(18):2257-64. Review.

Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D. *Epidemiol Infect*. 2006 Dec;134(6):1129-40.

Falk S, Kratzsch J, Paschke R, Koch CA. Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D. *Med Sci Monit*. 2007 Nov;13(11):CS133-136.

Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. *Int J Cancer*. 2007 Mar 1;120(5):1123-8.

Grant WB. The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaining links between skin cancers and solid tumours. *Eur J Cancer*. 2008 Jan;44(1):12-5.

Grant WB. Hypothesis-Ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. *Photochem Photobiol*. 2008 Jan 7; [Epub ahead of print]

Grant WB, Garland CF. A critical review of studies on vitamin D in relation to colorectal cancer. *Nutr Cancer*. 2004;48(2):115-23.

Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. *Anticancer Res.* 2006 Jul-Aug;26(4A):2687-99.

Grant WB, Garland CF, Gorham ED. An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. *Recent Results Cancer Res.* 2007;174:225-34.

Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr.* 2003 Nov;78(5):912-9.

Holick MF. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc.* 2006 Mar;81(3):353-73.

Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. *Curr Med Res Opin.* 2008;24:139-49.

McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? *FASEB J.* 2007 Dec 4; [Epub ahead of print]

Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. *Proc Natl Acad Sci U S A.* 2008 Jan 15;105(2):668-73.

Mookherjee N, Rehaume LM, Hancock RE. Cathelicidins and functional analogues as antisepsis molecules. *Expert Opin Ther Targets.* 2007;11(8):993-1004.

Mullin GE, Dobs A. Vitamin D and its role in cancer and immunity: a prescription for sunlight. *Nutr Clin Pract.* 2007 Jun;22(3):305-22.

Porojnicu A, Robsahm TE, Berg JP, Moan J. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: A possible role of sun-induced Vitamin D. *J Steroid Biochem Mol* 2007;103(3-5): 675-678.

Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P, Brennan P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. *Eur J Cancer.* 2007 May 29;43:1701-1712. (2 ISI, 1 GS)

Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. *J Steroid Biochem Mol Biol.* 2004 May;89-90(1-5):575-9. Review. (40 ISI, 51 GS)

Comment on “Vitamin D discovery outpaces FDA decision making”

“Before you let the sun in, make sure it wipes its shoes.” *Dylan Thomas, Under Milk Wood. 1954*

It is always wise to consider evidence from points of view other than those that are current ‘received wisdom’ so that we can see clearly what we are really looking at. Thus, the above review is of considerable interest ⁽¹⁾. The author postulates that circulating hormonal [activated] vitamin D (calcitriol) concentration is more important than circulating 25-hydroxyvitamin D [25-(OH)D] in the determination of tissue functions that are modulated by vitamin D. He also appears to suggest that changes in circulating 25-hydroxy vitamin D reflect changes in calcitriol formation and uptake rather than availability of vitamin D and that circulating calcitriol concentration tells us about vitamin D effectiveness. This would indeed be the case if all tissues depended on uptake of calcitriol from the circulation for their supplies of hormonal vitamin D. However, many tissues express the hydroxylase activating vitamin D and several have been confirmed as producers of calcitriol in situ. ⁽²⁻⁴⁾ Such tissues must use circulating 25-(OH)D, the substrate for activation by 25-hydroxyvitamin D 1-alpha-hydroxylase. Thus, for example, in the placenta, calcitriol is produced in large amounts from early in pregnancy with increases in circulating maternal calcitriol and reductions in maternal circulating 25-(OH)D ⁽⁴⁾. However, to suggest that all variation in serum 25-(OH)D concentrations in different disease processes reflects changes in local tissue vitamin D activation to the exclusion of variations due to the amount of vitamin D in the body would be to ignore the massive changes in serum 25-(OH)D seen within hours of exposure to UVB, without any changes in circulating calcitriol ⁽⁵⁾ and would not explain the remarkable seasonal variations in serum 25-(OH)D seen with variation in available effective UVB from sunlight, with variations in dietary intake of vitamin D and with supplement use. In Sweden for example, in a group of 116 women in the winter, an average serum 25(OH)D of 69 nmol/l was accounted for by the following; daily intake of normally fortified Swedish foods, 6.2 nmol/l; 3 fish meals/week, 25.5 nmol/l; regular vitamin supplement use, 11.0 nmol/l and a vacation in the sun within the last 6 months, 14.5 nmol/l leaving 11.8 nmol/l of 25-(OH)D to be accounted for the balance between incoming vitamin D and the amount of 25-(OH)D being consumed by local vitamin D activating tissues ^(6,7). In addition, however much ultraviolet B effective for induction of vitamin D synthesis [effUVB] one is exposed to vitamin D toxicity does not develop because of feed-back mechanisms in the skin itself ⁽⁸⁾. Similarly, feed back mechanisms ensure that circulating calcitriol is virtually unchanged in the face of reductions in serum 25-(OH)D in the circulation until there is clinically obvious vitamin D deficiency with bone disease such as rickets or osteomalacia when calcitriol does eventually fall though even then, in some case, serum calcitriol is found to be increased. ⁽⁹⁾ These findings challenge the argument that vitamin D modulation of tissue function depends predominantly on circulating calcitriol and explain why vitamin D repletion continues to be judged at present by circulating concentrations of the storage adduct, 25-(OH)D, acting as it does as the substrate for local tissue activation throughout the body and not just in the kidney. In support of this position it is well known that measurement of circulating calcitriol [hormonally active 1,25dihydroxyvitamin D] is unhelpful in the

assessment of vitamin D repletion since its concentrations are normally so tightly regulated across a wide range of concentrations of 25-(OH)D. ⁽¹⁰⁾ Finally, the fact that vitamin D activation has been demonstrated in several of the extra-renal human tissues known to express specific vitamin D activating 1-alpha hydroxylase supports the view that assessment of substrate availability of vitamin D, as reflected by serum 25-(OH)D, is likely to be of importance in the assessment of vitamin D repletion in humans.

1. Marshall TG. Vitamin D discovery outpaces FDA decision making. **BioEssays** **2008**;30.2:173-182
2. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS. Extra-renal 25-hydroxyvitamin D₁alpha-hydroxylase in human health and disease. **J Steroid Biochem Mol Biol** **2007**; 103:316-21
3. Merke J, Milde P, Lewicka S, Hugel U, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. **J Clin Invest** **1989** 83:1903-15
4. Evans KN, Bulmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidual function. **J Soc Gynecol Investig** **2004**; 11:263-71
5. Landin-Wilhelmsen K, Wilhelmsen L, Wilske J, Lappas G, Rosen T, Lindsted G, Lundberg PA, Bengtsson BA. Sunlight increases serum 25(OH) vitamin D concentration whereas 1,25(OH)₂D₃ is unaffected. Results from a general population study in Goteborg, Sweden (The WHO MONICA Project). **Eur J Clin Nutr** **1995**; 49:44-407
6. Engelsen O, Brustad M, Aksnes L, Lund E. Daily duration of vitamin D synthesis in human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud thickness. **Photochem Photobiol** **2005**; 81:1287-90
7. Burgaa A, Akesson A, Oster A, Michaelsson K, Wolk A. Associations of diet, supplement use and ultraviolet B radiation exposure with vitamin D status in Swedish women during winter **Am J Clin Nutr** **2007**; 86:404
8. Bickle DD. Vitamin D and Skin. Chapter 25 in Vitamin D. Ed. Feldman D, Glorieux FH, Wesley Pike J. 1997: 379-394
9. Pettifor JM, Daniels ED. Vitamin D deficiency and nutritional rickets in children. Chapter 42 in Vitamin D. Ed. Feldman D, Glorieux FH, Wesley Pike J. 1997: 663-678.
10. Hollis B. Detection of vitamin D and its major metabolites. Chapter 38 in Vitamin D. Ed. Feldman D, Glorieux FH, Wesley Pike J. 1997;587-606.

Barbara J Boucher, MD, FRCP

Centre for Diabetes & Metabolic Medicine
Barts & the London Medical & Dental School
London, UK